JPRN-UMIN000024505已完成未知
ow-dose gemcitabine plus nab-paclitaxel versus standard-dose gemcitabine plus nab-paclitaxel in elderly patients with metastastic pancreatic cancer: A randomized phase II trial - Low-dose gemcitabine plus nab-paclitaxel versus standard-dose gemcitabine plus nab-paclitaxel in elderly patients with metastastic pancreatic cancer
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 65years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Pulmonary fibrosis/pneumonia interstitialis 2)Serous diarrhea 3)Active infection 4)Serious complication 5)modelate or severe pleural effusion/ascites 6)Brain metastasis with sympsons 7)Active multiple primary cancer 8)Use of warfarin potassium 9)During pregnancy 10)Serious mental disorders 11)The other inappropriate case
研究者
相似试验
已完成
不适用
Gemcitabine Plus Paclitaxel versus Gemcitabine alone in Patients with Recurrent or Advanced Urothelial Cancer previously Treated With Cisplatin-based Chemotherapy: A randomized Phase II studyrothelial cancerJPRN-UMIN000002450Teikyo University80
已完成
2 期
Phase II study of Gemcitabine + nab-paclitaxel as first-line therapy for locally advanced pancreatic cancerlocally advanced unresectable pancreatic cancerJPRN-UMIN000016852Kurume university school of medicine24
招募中
不适用
Safety and efficacy of nab-paclitaxel plus gemcitabine in the patients with recurrent pancreatic cancer after pancreatectomypancreatic cancerJPRN-UMIN000031203niversity of Yamanashi30
已完成
不适用
eoadjuvant nab-paclitaxel plus gemcitabine therapy for resectable pancreatic cancer; A phase II multicenter trialResectable pancreatic cancerJPRN-UMIN000031822Hokkaido Pancreatic Cancer Study Group (HOPS)50
进行中（未招募）
2 期
eoadjuvant nab-paclitaxel plus gemcitabine therapy for resectable pancreatic cancer; A phase II multicenter trialJPRN-jRCT1011180032Hirano Satoshi50